Our in vivo data are in line with the data of Klein and colleagues, showing, in murine models of human cancers, such as leukemia, breast or lung cancer, FAP-IL-2v efficacy when combined with therapeutic Ab directed against tumor antigens [6]. This evidence concerns the gene FAP and leukemia.